Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 5, 2026, 6:07 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 242 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Medical Oncology Clear all

Conditions: Epidermal Growth Factor Receptor (EGFR)-Mutated Non Small Cell Lung Cancer
Interventions: HER3-DXd; Drug
Lead sponsor: Daiichi Sankyo; Industry
Eligibility: 18 Years and older
U.S. locations: 21
States / cities: Springdale, Arkansas • Los Angeles, California • Aurora, Colorado + 16 more

Conditions: Craniopharyngioma, Child
Interventions: Tumor and Blood Specimens; Procedure
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 30 Days to 21 Years
Enrollment: 250 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2030
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Gastrointestinal Stromal Tumors
Interventions: Masitinib, Imatinib; Drug
Lead sponsor: AB Science; Industry
Eligibility: 18 Years and older
Enrollment: 335 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2018
U.S. locations: 7
States / cities: Orlando, Florida • Atlanta, Georgia • Detroit, Michigan + 4 more

Conditions: Breast Neoplasms
Interventions: Non-Interventional, Automated Whole Breast Ultrasound; Other · Device
Lead sponsor: Delphinus Medical Technologies, Inc.; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 1,150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2021
U.S. locations: 10
States / cities: Los Angeles, California • Miami Beach, Florida • Savannah, Georgia + 7 more

Conditions: Advanced Breast Cancer
Interventions: Guardant360 test; Diagnostic Test
Lead sponsor: Guardant Health, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 109 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: Redwood City, California

Conditions: Breast Cancer
Interventions: Imagio OA/US (US and OA/US), Imagio gray scale ultrasound; Device
Lead sponsor: Seno Medical Instruments Inc.; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 2,105 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2015
U.S. locations: 16
States / cities: Murrieta, California • Englewood, Colorado • New Haven, Connecticut + 13 more

Conditions: CNS Tumor
Interventions: Not listed
Lead sponsor: Arbor Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 272 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2025
U.S. locations: 31
States / cities: Huntsville, Alabama • Phoenix, Arizona • Scottdale, Arizona + 28 more

Conditions: Head and Neck Carcinoma
Interventions: Medical Chart Review, Questionnaire Administration; Other
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 450 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2032
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Medical Oncology, Integrative Oncology, Medical Nutrition Therapy
Interventions: Diet; Other
Lead sponsor: State University of New York at Buffalo; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2028
U.S. locations: 1
States / cities: Buffalo, New York

Conditions: Malignant Brain Tumors
Interventions: Survey; Behavioral
Lead sponsor: Tufts Medical Center; Other
Eligibility: 16 Years and older
Enrollment: 225 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2025
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage IA Breast Cancer AJCC v8, Anatomic Stage IB Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIA Breast Cancer AJCC v8, Anatomic Stage IIB Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, Anatomic Stage IIIB Breast Cancer AJCC v8, Anatomic Stage IIIC Breast Cancer AJCC v8, Prognostic Stage I Breast Cancer AJCC v8, Prognostic Stage IA Breast Cancer AJCC v8, Prognostic Stage IB Breast Cancer AJCC v8, Prognostic Stage II Breast Cancer AJCC v8, Prognostic Stage IIA Breast Cancer AJCC v8, Prognostic Stage IIB Breast Cancer AJCC v8, Prognostic Stage III Breast Cancer AJCC v8, Prognostic Stage IIIA Breast Cancer AJCC v8, Prognostic Stage IIIB Breast Cancer AJCC v8, Prognostic Stage IIIC Breast Cancer AJCC v8, Stage I Prostate Cancer AJCC v8, Stage II Prostate Cancer AJCC v8, Stage IIA Prostate Cancer AJCC v8, Stage IIB Prostate Cancer AJCC v8, Stage IIC Prostate Cancer AJCC v8, Stage III Prostate Cancer AJCC v8, Stage IIIA Prostate Cancer AJCC v8, Stage IIIB Prostate Cancer AJCC v8, Stage IIIC Prostate Cancer AJCC v8, Stage IVA Prostate Cancer AJCC v8
Interventions: Survey Administration; Other
Lead sponsor: University of Southern California; Other
Eligibility: 18 Years and older
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Oncology
Interventions: Once time de-identified Qualtrics survey; Other
Lead sponsor: Abramson Cancer Center at Penn Medicine; Other
Eligibility: Not listed
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Childhood Cancer, Cerebral Palsy, Chronic Lung Disease, Congenital Heart Disease, Congenital Metabolic Disorder, Gastrostomy
Interventions: GoalKeeper, Standard Care; Other
Lead sponsor: Stanford University; Other
Eligibility: 18 Years and older
Enrollment: 67 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: Palo Alto, California

Conditions: Inflammatory Breast Carcinoma, Invasive Breast Carcinoma, Second Primary Malignant Neoplasm
Interventions: Biospecimen Collection, Interview, Medical Chart Review, Questionnaire Administration; Procedure · Other
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 1,200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2030
U.S. locations: 10
States / cities: Gilbert, Arizona • La Jolla, California • Greeley, Colorado + 6 more

Conditions: Non-metastatic Prostate Cancer, Non-metastatic Castration-resistant Prostate Cancer
Interventions: Darolutamide (Nubeqa, BAY1841788), Enzalutamide, Apalutamide; Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 1,800 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024
U.S. locations: 1
States / cities: Whippany, New Jersey

Conditions: Nausea, Vomiting and Anxiety Associated With Medical Oncology Patients
Interventions: Peppermint and Lavender Essential Oils; Drug
Lead sponsor: Central DuPage Hospital; Other
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2014
U.S. locations: 1
States / cities: Winfield, Illinois

Conditions: Chronic Lymphocytic Leukemia
Interventions: Not listed
Lead sponsor: AstraZeneca; Industry
Eligibility: Not listed
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 16
States / cities: Fountain Valley, California • Redlands, California • Boca Raton, Florida + 13 more

Conditions: Cancer
Interventions: Long-term follow-up of cerena™, Long-term follow-up of attune™; Device
Lead sponsor: Blue Note Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 350 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Metastatic Prostatic Adenocarcinoma
Interventions: Docetaxel, Degarelix; Drug
Lead sponsor: Medical University of South Carolina; Other
Eligibility: 18 Years and older · Male only
Enrollment: 52 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2024
U.S. locations: 1
States / cities: Charleston, South Carolina

Conditions: Fibroid Uterus, Fibroid Tumor, Leiomyoma, Fibromyoma, Leiomyoma, Uterine
Interventions: Simvastatin 40mg, Placebo 40 mg; Drug
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years to 55 Years · Female only
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2026
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Squamous Non-small Cell Lung Cancer
Interventions: Second line (2L) afatinib, Second line chemotherapy; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 18 Years and older
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020
U.S. locations: 1
States / cities: Dublin, Ohio

Conditions: Cancer, Brain Tumor, Solid Tumor, Leukemia, Lymphoma
Interventions: Not listed
Lead sponsor: St. Jude Children's Research Hospital; Other
Eligibility: 13 Years and older
Enrollment: 25 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2019
U.S. locations: 1
States / cities: Memphis, Tennessee

Conditions: Lung Cancer, Pulmonary Nodule, Solitary
Interventions: Optellum Virtual Nodule Clinic; Device
Lead sponsor: Abramson Cancer Center at Penn Medicine; Other
Eligibility: 35 Years to 89 Years
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2030
U.S. locations: 3
States / cities: Philadelphia, Pennsylvania

Conditions: Breast Cancer Female, Early-stage Breast Cancer
Interventions: Lumpectomy, Intraoperative Radiation Therapy; Procedure · Radiation
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 55 Years and older · Female only
Enrollment: 94 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2033
U.S. locations: 1
States / cities: Macon, Georgia

Search by objective public record fields.

Medical Access Program for Patritumab Deruxtecan

Prospective Pilot Study Identifying Clinically Relevant Biological Targets for Medical Therapy

Masitinib in First Line Treatment of Gastro-Intestinal Stromal Tumor (GIST)

Delphinus SoftVue Prospective Case Collection - ARM 2

Guardant360® Related Clinical Outcomes in Patients Who Share Medical Records-Breast Cancer

The PIONEER-01 Study of the Imagio Breast Imaging System

Vigilant ObservatIon of GlIadeL WAfer ImplaNT Registry

Medical Data Collection of Patients With Head and Neck Cancer Treated With Proton Therapy

A Pilot and Feasibility Study of a Dietary Intervention With Low-protein Meals in Cancer Patients Receiving Immunotherapies

Expert Consensus and Artificial Intelligence in Medical Decision Making in Patients with Malignant Brain Tumors

Health Literacy in Understanding Radiation Therapy Information in Patients Undergoing Definitive Radiation Therapy

Assessing Perceptions of ML Explanations by Medical Oncologists

GoalKeeper: Intelligent Information Sharing for Children With Medical Complexity

Biospecimen and Medical Data Collection and Tumor Biopsy in Creating Research Tissue Registry in Patients With Inflammatory or Invasive Breast Cancer

An Observational Study to Learn More About the Use of Androgen Receptor Inhibitors and How They Affect Men With Nonmetastatic Prostate Cancer in Routine Medical Care in the United States

The Use of Aromatherapy for Symptom Management

MEOI and HRQoL in CLL Patients Treated With BTKis

Long-term Follow-up of RESTORE Study

Phase II Study of Docetaxel Before Degarelix in Patients With Newly Diagnosed Metastatic Prostate Cancer.

Effects of Simvastatin on Uterine Leiomyoma Size

A Study in the United States Using Electronic Medical Records (EMR) to Assess Effectiveness of Afatinib (Gilotrif) Following Pembrolizumab and Chemotherapy in the Treatment of Metastatic Squamous Cell Carcinoma of the Lung

Medical Treatment Decision Making Using Adaptive Conjoint Analysis

Assessment of a Radiomics-based Computer-Aided Diagnosis Tool for Pulmonary nodulES

IORT-Breast at Medical Center Navicent Health